ArticleCancer medicine2019

Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.

Satomi Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.